Identification of N-arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors.
William J RedmondErin E CawstonNatasha L GrimseyJordyn StuartAmelia R EdingtonMichelle GlassMark ConnorPublished in: British journal of pharmacology (2015)
NADA is an ineffective agonist at most canonical cannabinoid receptor signalling pathways, but did promote mobilization of [Ca]i via Gq -dependent processes and some CB1 receptor trafficking. This signalling profile is distinct from that of any known cannabinoid, and suggests that NADA may have a unique spectrum of effects in vivo. Our results also indicate that it may be possible to identify highly biased CB1 receptor ligands displaying a subset of the pharmacological or therapeutic effects usually attributed to CB1 ligands.
Keyphrases